Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 12:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Bolus Administered Clear all
Completed Phase 1 Interventional

Study of EC0489 for the Treatment of Refractory or Metastatic Tumors

NCT00852189
View directory record Official record
Conditions
Cancer
Interventions
EC0489, Injection, EC20
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
6
States / cities
Lafayette, Indiana • Baltimore, Maryland • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

N-acetylcysteine and NMDA Antagonist Interactions

NCT00611897
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
N-acetylcysteine and ketamine, placebo and ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 23, 2026, 12:39 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer

NCT01227408
View directory record Official record
Conditions
Breast Cancer
Interventions
doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Programmed Intermittent Bolus Dosing Versus Continuous Epidural Infusion for Epidural Analgesia in Abdominal Surgery.

NCT03307174
View directory record Official record
Conditions
Pain, Acute
Interventions
Bupivacaine, Fentanyl
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV

NCT05471076
View directory record Official record
Conditions
HIV-1-infection
Interventions
426c.Mod.Core-C4b 30 mcg, 426c.Mod.Core-C4b 100 mcg, 426c.Mod.Core-C4b 300 mcg, Placebo, BG505
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 23, 2026, 12:39 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Reversing Glucose and Lipid-mediated Vascular Dysfunction

NCT04832009
View directory record Official record
Conditions
Blood Pressure, Hypertension
Interventions
Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 2 Interventional Results available

Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19

NCT04570384
View directory record Official record
Conditions
Acute Hypoxemic Respiratory Failure
Interventions
L-Citrulline, Placebo
Drug
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 4 Interventional Results available

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI

NCT03247738
View directory record Official record
Conditions
ST Segment Elevation Myocardial Infarction, Percutaneous Coronary Intervention
Interventions
Cangrelor, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Not applicable Interventional Results available

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients

NCT00651755
View directory record Official record
Conditions
Lymphoma
Interventions
Aprepitant, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab, Ondansetron
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Testing the Feasibility of Patient Controlled Sedation for Ventilated ICU Patients

NCT01606852
View directory record Official record
Conditions
Acute Respiratory Failure, Anxiety
Interventions
Dexmedetomidine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Whole Body Distribution and Radiation Dosimetry of the Positron Emission Tomography Ligand Fluoride-18 (18F)-JNJ-64326067 in Healthy Participants

NCT03581916
View directory record Official record
Conditions
Healthy
Interventions
18F-JNJ-64326067
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide

NCT01932970
View directory record Official record
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
40
States / cities
Alhambra, California • Azusa, California • Bakersfield, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 23, 2026, 12:39 PM EDT
Active, not recruiting Phase 3 Interventional

Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH

NCT05995405
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage (aSAH)
Interventions
GTX-104, Nimotop 30 MG Oral Capsule
Drug
Lead sponsor
Grace Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 4 Interventional Results available

Dexmedetomidine and Propofol for Pediatric MRI Sedation

NCT03513757
View directory record Official record
Conditions
Headache, Tumor, Seizure Disorder, Neurofibromatoses, Hydrocephalus, Abdominal Neoplasm, Spine Deformity
Interventions
propofol, Dexmedetomidine, Glycopyrrolate, Lidocaine 1% Injectable Solution, Nitrous Oxide, Sevoflurane
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
12 Months to 60 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Sep 23, 2026, 12:39 PM EDT
Terminated Phase 3 Interventional

A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

NCT03145831
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Somavaratan
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
3 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Continuous TAP Blocks: Relative Effects of a Basal Infusion vs. Repeated Bolus Doses

NCT02662023
View directory record Official record
Conditions
Postoperative Pain
Interventions
Bolus, Basal
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 23, 2026, 12:39 PM EDT
Terminated Not applicable Interventional Results available

Effect of Remifentanil on Hemodynamic Stability During Placement of a Mayfield Head Fixation Device for Craniotomy

NCT02430389
View directory record Official record
Conditions
Surgery
Interventions
Remifentanil, Normal Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

NCT01405508
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 23, 2026, 12:39 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)

NCT01697930
View directory record Official record
Conditions
Solid Malignancy, Lymphoma
Interventions
[18F] 4-L-Fluoroglutamine (2S,4R)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 90 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 23, 2026, 12:39 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Subanesthetic IV Bolus Ketamine in the Treatment of Acute Depression

NCT02378415
View directory record Official record
Conditions
Acute Depression
Interventions
Ketamine, Placebo
Drug
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Sep 23, 2026, 12:39 PM EDT
Not listed Phase 2 Interventional

Methylene Blue as a Third-line Vasopressor in Septic Shock

NCT04089072
View directory record Official record
Conditions
Septic Shock
Interventions
Methylene Blue, Phenylephrine
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Analgesic Efficacy of Interscalene Nerve Block Versus Local Infiltration Analgesia Following Total Shoulder Arthroplasty

NCT02876055
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Single shot interscalene nerve block, Continuous interscalene nerve block, Local Infiltration Analgesia (LIA)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 3 Interventional

Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration

NCT07269808
View directory record Official record
Conditions
Anesthesia, Sedation, Endoscopy
Interventions
Remimazolam, Propofol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1Phase 2 Interventional

YSPSL for Prevention of Delayed Graft Function Part B

NCT00298168
View directory record Official record
Conditions
Kidney Diseases
Interventions
YSPSL, placebo
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2008 · Synced Sep 23, 2026, 12:39 PM EDT